These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1719 related items for PubMed ID: 7608274

  • 1. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A, Yamada T, Aizawa T, Ichikawa K, Komiya I, Takasu N, Takemura Y.
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [Abstract] [Full Text] [Related]

  • 2. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T, Koizumi Y, Sato A, Hashizume K, Aizawa T, Takasu N, Nagata H.
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [Abstract] [Full Text] [Related]

  • 3. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E, Gardini E, Minelli R, Bianconi L, Salvi M, Gavaruzzi G, Braverman LE.
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [Abstract] [Full Text] [Related]

  • 4. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M, Koizumi Y, Aizawa T, Yamada T, Takahashi Y, Watanabe T, Kamoi K.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sensitivity of thyroids to endogenous thyrotrophin in patients with Graves' disease.
    Tamai H, Nagai K, Uehata S, Komaki G, Kiyohara K, Miyauchi A, Kuma K, Kumagai LF, Nagataki S.
    Exp Clin Endocrinol; 1990 Dec; 96(3):279-87. PubMed ID: 2128053
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ, Lee BW, Kim JY, Jung JH, Min YK, Lee MS, Lee MK, Kim KW, Chung JH.
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [Abstract] [Full Text] [Related]

  • 12. [Serum thyroid hormones and TSH response to TRH during treatment of Graves' disease by carbimazole (author's transl)].
    Lorcy Y, Heim J, Auvray E, Allannic H.
    Ann Endocrinol (Paris); 1979 Dec; 40(4):441-2. PubMed ID: 117739
    [Abstract] [Full Text] [Related]

  • 13. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T, Ishihara M, Koizumi Y, Hashizume K, Takasu N, Yamada T, Kobayashi I, Watanabe T, Shimizu Z.
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [Abstract] [Full Text] [Related]

  • 14. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, Kumagai LF, Nagataki S.
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [Abstract] [Full Text] [Related]

  • 15. [Variation of the thyrotropin-releasing-hormone (TRH) stimulated thyrotropin (TSH) response in comparison with the tyhroid-gland-suppression test and the triiodothyronine (T3) and thyroxine (T4) blood levels in the so-called euthyroid endocrine ophthalmopathy].
    Wenzel KW.
    Endokrinologie; 1975 Sep; 66(1):67-73. PubMed ID: 1243821
    [Abstract] [Full Text] [Related]

  • 16. The thyrotrophin response to thyrotrophin releasing hormone during treatment in patients with Graves' disease.
    Haug E, Frey HM, Sand T.
    Acta Endocrinol (Copenh); 1977 Jun; 85(2):335-44. PubMed ID: 405834
    [Abstract] [Full Text] [Related]

  • 17. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T, Sato A, Komiya I, Nishimori T, Ito Y, Terao A, Eto S, Tanaka Y.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [Abstract] [Full Text] [Related]

  • 18. Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy.
    Hoffman DP, Surks MI, Oppenheimer JH, Weitzman ED.
    J Clin Endocrinol Metab; 1977 May; 44(5):892-901. PubMed ID: 404309
    [Abstract] [Full Text] [Related]

  • 19. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E, Minelli R, Gardini E, Bianconi L, Salvi M, Gavaruzzi G, Ugolotti G, Braverman LE.
    J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.